{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=All-Trans+Retinoic+Acid+%28ATRA%29&page=2",
    "query": {
      "intervention": "All-Trans Retinoic Acid (ATRA)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=All-Trans+Retinoic+Acid+%28ATRA%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=All-Trans+Retinoic+Acid+%28ATRA%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T15:16:14.316Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01456468",
      "title": "Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cholangitis, Sclerosing"
      ],
      "interventions": [
        {
          "name": "Oral all-trans retinoic acid (ATRA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 19,
      "start_date": "2011-10",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Rochester, Minnesota",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01456468"
    },
    {
      "nct_id": "NCT03999684",
      "title": "A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-08-05",
      "completion_date": "2020-04-15",
      "has_results": true,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999684"
    },
    {
      "nct_id": "NCT01161550",
      "title": "Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "Granulocyte colony-stimulating factor (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "All-Trans Retinoic Acid (ATRA)",
          "type": "DRUG"
        },
        {
          "name": "Midostaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-11",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-07-23",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01161550"
    },
    {
      "nct_id": "NCT00675870",
      "title": "Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "NRX 195183 Soft Gelatin Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NuRx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-05-12",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675870"
    },
    {
      "nct_id": "NCT00100906",
      "title": "Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "ATRA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2004-08",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-08-16",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100906"
    },
    {
      "nct_id": "NCT02339740",
      "title": "Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"
      ],
      "interventions": [
        {
          "name": "Arsenic Trioxide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mitoxantrone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 158,
      "start_date": "2015-07-21",
      "completion_date": "2029-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339740"
    },
    {
      "nct_id": "NCT01183429",
      "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "3F8 and 13-cis-retinoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 39,
      "start_date": "2010-08-12",
      "completion_date": "2018-09-13",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183429"
    },
    {
      "nct_id": "NCT00326170",
      "title": "Phase II 5-Azacytidine Plus VPA Plus ATRA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "5-Azacytidine (5-aza)",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "All-Trans Retinoic Acid (ATRA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2005-07",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2012-06-15",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326170"
    },
    {
      "nct_id": "NCT00004188",
      "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "isotretinoin",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 495,
      "start_date": "2001-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-17",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004188"
    },
    {
      "nct_id": "NCT04305041",
      "title": "Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quavonlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vibostolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "ATRA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-06-26",
      "completion_date": "2025-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-04T15:16:14.316Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305041"
    }
  ]
}